Clinical Trial

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 17, 2023 (before its estimated April 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months. The study ends after 252 included patients completed the study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-04; most recent amendment 2023-05-15.
Trial Details
NCT Number NCT05367089
Lead Sponsor Maastricht University Medical Center
Collaborators: Zuyderland Medical Centre
Conditions Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
Enrollment 252 participants
Start Date 2022-08-22
Primary Completion 2026-04-22 (estimated)
Study Completion 2027-04-22 (estimated)
Updated on ClinicalTrials.gov 2023-05-17